Serveur d'exploration Chloroquine - Exploration (Accueil)

Index « Titre (en) » - entrée « safety »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
safer < safety < saha  Facettes :

List of bibliographic references indexed by safety

Number of relevant bibliographic references: 44.
Ident.Authors (with country if any)Title
000025 (2020) Qi Wang [République populaire de Chine] ; Mengqi Luo [République populaire de Chine] ; Bo Xiang [République populaire de Chine] ; Siyuan Chen [République populaire de Chine] ; Yi Ji [République populaire de Chine]The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis
000444 (2019) Gulsen Ozen [États-Unis] ; Sofia Pedro [États-Unis] ; Rebecca Schumacher [États-Unis] ; Teresa A. Simon [États-Unis] ; Kaleb Michaud [États-Unis]Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
000678 (2019) Kevin L. Winthrop ; Kenneth Saag ; Matthew D. Cascino ; Jinglan Pei ; Ani John ; Angelika Jahreis ; Tmirah Haselkorn ; Daniel E. FurstLong‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
000852 (2019) Peter C. Taylor ; Didier Saurigny [Royaume-Uni] ; Jiri Vencovsky [République tchèque] ; Tsutomu Takeuchi [Japon] ; Tadashi Nakamura [Japon] ; Galina Matsievskaia [Russie] ; Barbara Hunt [États-Unis] ; Thomas Wagner [Suisse] ; Bernard Souberbielle [Royaume-Uni]Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial
000853 (2019) John Tesser [États-Unis] ; Shelly Kafka [États-Unis] ; Raphael J. Dehoratius [États-Unis] ; Stephen Xu [États-Unis] ; Elizabeth C. Hsia [États-Unis] ; Anthony Turkiewicz [États-Unis]Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age
000C73 (2017-04) Tiphaine Gaillard [France] ; Sebastien Briolant [Sénégal, France] ; Marylin Madamet [Sénégal, France] ; Bruno Pradines [Sénégal, France]The end of a dogma: the safety of doxycycline use in young children for malaria treatment
000F05 (2015) Kwan-Hwa Chi [Taïwan] ; Hui-Ling Ko [Taïwan] ; Kai-Lin Yang [Taïwan] ; Cheng-Yen Lee [Taïwan] ; Mau-Shin Chi [Taïwan] ; Shang-Jyh Kao [Taïwan]Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
000F27 (2015) L. Cummins [Australie] ; V. S. Katikireddi [Australie] ; S. Shankaranarayana [Australie] ; K. Y. C. Su [Australie] ; E. Duggan [Australie] ; V. Videm [Australie, Norvège] ; H. Pahau [Australie] ; R. Thomas [Australie]Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis
001197 (2013) Penny ThorntonMedication Safety Series
001225 (2013) Jin Zhou [République populaire de Chine] ; Zhong Wu [République populaire de Chine] ; Zongguang Zhou [République populaire de Chine] ; Zhiqiang Wang [République populaire de Chine] ; Yi Liu [République populaire de Chine] ; Xiang-Yang Huang [République populaire de Chine] ; Bing Peng [République populaire de Chine]Efficacy and safety of laparoscopic splenectomy in thrombocytopenia secondary to systemic lupus erythematosus
001257 (2013) G. Hakobyan ; V. Vardanyan [Arménie]AB0372 Safety of hydroxychloroquine in pregnant women with systemic lupus erythematosus and rheumatoid arthritis.
001411 (2012) Sengwee Toh [États-Unis] ; Lingling Li [États-Unis] ; Leslie R. Harrold [États-Unis] ; Elizabeth A. Bayliss [États-Unis] ; Jeffrey R. Curtis [États-Unis] ; Liyan Liu [États-Unis] ; Lang Chen [États-Unis] ; Carlos G. Grijalva [États-Unis] ; Lisa J. Herrinton [États-Unis]Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
001511 (2011) Pieter C. Goeminne [Belgique] ; Patrick Verschueren [Belgique] ; Hans Scheers [Belgique] ; Lieven J. Dupont [Belgique]Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis
001732 (2010) Current awareness: Pharmacoepidemiology and drug safety
001746 (2010) Ewa Wi Sik-Szewczyk [Pologne] ; Magdalena Romanowska [Pologne] ; Paweł Mielnik [Pologne] ; Hanna Chwali Ska-Sadowska [Pologne] ; Lidia B. Brydak [Pologne] ; Marzena Olesi Ska [Pologne] ; Jakub Z Bek [Pologne]Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety
001848 (2009) N. Varatharajan [Australie] ; I. G. S. Lim ; A. Anandacoomarasamy ; R. Russo ; K. Byth [Australie] ; D. G. Spencer ; N. Manolios ; G. B. Howe [Australie]Methotrexate: long‐term safety and efficacy in an Australian consultant rheumatology practice
001853 (2009) C. Salliot [France] ; D. Van Der Heijde [Pays-Bas]Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
001883 (2009) Current awareness: Pharmacoepidemiology and drug safety
001884 (2009) Current awareness: Pharmacoepidemiology and drug safety
001A13 (2008) Current awareness: Pharmacoepidemiology and drug safety
001A14 (2008) Current awareness: Pharmacoepidemiology and drug safety
001A15 (2008) Current awareness: Pharmacoepidemiology and drug safety
001B62 (2007) Current awareness: Pharmacoepidemiology and drug safety
001B63 (2007) Current awareness: Pharmacoepidemiology and drug safety
001B64 (2007) Current awareness: Pharmacoepidemiology and drug safety
001C51 (2006) A. Wozniacka [Pologne] ; I. Cygankiewicz [Pologne] ; M. Chudzik [Pologne] ; A. Sysa-J Drzejowska ; Jk Wranicz [Pologne]The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters
001C62 (2006) A. Holvast [Pays-Bas] ; A. Huckriede [Pays-Bas] ; J. Wilschut [Pays-Bas] ; G. Horst [Pays-Bas] ; J J C. De Vries [Pays-Bas] ; C A Benne [Pays-Bas] ; C G M. Kallenberg [Pays-Bas] ; M. Bijl [Pays-Bas]Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease
001D51 (2006) Current awareness: Pharmacoepidemiology and drug safety
001D52 (2006) Current awareness: Pharmacoepidemiology and drug safety
001D53 (2006) Current awareness: Pharmacoepidemiology and drug safety
001E38 (2005) M. Sterba [République tchèque] ; T. Simunek [République tchèque] ; Y. Mazurová ; M. Adamcová ; O. Popelová ; J. Kaplanová [République tchèque] ; P. Ponka [Canada] ; V. Gersl [République tchèque]Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits
001E77 (2005) J. Wenzel [Allemagne] ; S. Br Hler [Allemagne] ; R. Bauer [Allemagne] ; T. Bieber [Allemagne] ; T. Tüting [Allemagne]Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients
001E85 (2005) Current awareness: Pharmacoepidemiology and drug safety
001E86 (2005) Current awareness: Pharmacoepidemiology and drug safety
002004 (2004) Current awareness: Pharmacoepidemiology and drug safety
002119 (2003) Current Awareness: Pharmacoepidemiology and Drug Safety
002343 (2001) Pharmacoepidemiology and drug safety
002917 (1997) Carlos D. Rose [États-Unis] ; Bernhard H. Singsen [États-Unis] ; Andrew H. Eichenfield [États-Unis] ; Donald P. Goldsmith [États-Unis] ; Balu H. Athreya [États-Unis]Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis
002A28 (1996) Pharmacoepidemiology and drug safety
002A29 (1996) Pharmacoepidemiology and drug safety
002C73 (1994) Pharmacoepidemiology and drug safety
002D78 (1993) Pharmacoepidemiology and drug safety
003741 (1982) Robert F. Harrison ; Joseph Ennis ; Mary BrennanCrying wolf on drug safety
003742 (1982) Crying wolf on drug safety.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "safety" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "safety" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    safety
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021